A look at the key issues impacting China’s recovery post-COVID-19 and stock market performance year to date.
China: Moderation Expected After a Steady Early Recovery
Why secular growth leadership will likely continue
Portfolio Manager Doug Rao discusses the outperformance of secular growth companies and the themes that have allowed this leadership to become more entrenched during the COVID-19 pandemic.
What a Return to “Normal” Could Mean for Equities
In our ongoing video series on COVID-19, a discussion of the pandemic’s trajectory, vaccine development and investment considerations post-crisis.
Plan Sponsors: Are You Listening to Participants?
For retirement plan sponsors, listening to participants to understand their needs is more important than ever during these challenging times.
Henderson High Income AGM
Watch Fund Manager David Smith present on how the Trust has performed over the last financial year and his outlook for the coming months.
Sustainable Investing Shines During Market Gloom
Research shows that 70% of sustainable equity funds ranked in the top half of their Morningstar category during the first quarter of 2020. Here’s why.
The shape of credit (English)
Portfolio managers on the Absolute Return Income Strategy look at the factors shaping credit markets from central bank support to potential resilience from financials.
Podcast: Understanding the science and investment implications of COVID-19 (part 7)
In our ongoing series on COVID-19, Portfolio Manager and Research Analyst Dan Lyons and Director of Research Matt Peron discuss the current state of the pandemic and what investors should consider as the economy tries to return to “normal.”
Surviving to Thriving: Secular Technology Themes Accelerating As A Result of COVID-19
Portfolio Manager Denny Fish discusses how the convergence of secular technology themes is creating opportunities for forward-looking investors amid the coronavirus pandemic.
What a Return to “Normal” Could Mean for Equities
In our ongoing video series on COVID-19, a discussion of the pandemic’s trajectory, vaccine development and investment considerations post-crisis.